The FDA’s draft guidance on risk-based approaches to monitoring has generated significant interest and myriad discussions within the industry. However, the rate of adoption of risk-based monitoring approaches has to-date been slower than many industry experts expected. This podcast takes a closer look at the primary concerns expressed along with current approaches, and discusses best practices in adopting a successful risk-based monitoring practice.